The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes

References

• Gray SP, Jandeleit-Dahm K. The pathobiology of diabetic vascular complications – cardiovascular and kidney disease. J Mol Med (Berl) 2014;92:441–52
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013;93:137–88
   PubMed Web of Science ®Google Scholar
• Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058–70
   PubMed Web of Science ®Google Scholar
• EDIC Study. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. J Am Med Assoc 2003;290:2159–67
   Web of Science ®Google Scholar
• Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009;15:1298–306
   PubMed Web of Science ®Google Scholar
• Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007;13:1349–58
   PubMed Web of Science ®Google Scholar
• Romeo G, Liu WH, Asnaghi V, et al. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 2002;51:2241–8
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014;79:34–74
   PubMed Web of Science ®Google Scholar
• Akhtar S, Benter IF. The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. BioImpacts 2013;3:5–9
   PubMedGoogle Scholar
• Matrougui K. Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinase. Diabetes Metab Res Rev 2010;26:13–16
   PubMed Web of Science ®Google Scholar
• Benter IF, Yousif MH, Griffiths SM, et al. Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. Br J Pharmacol 2005;145:829–36
   PubMed Web of Science ®Google Scholar
• Benter IF, Yousif MH, Hollins AJ, et al. Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase. J Vasc Res 2005;42:284–91
   PubMed Web of Science ®Google Scholar
• Yousif MH, Benter IF, Akhtar S. The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Auton Autacoid Pharmacol 2005;25:69–78
   PubMedGoogle Scholar
• Akhtar S, Yousif MH, Dhaunsi GS, et al.. Angiotensin-(1–7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol 2012;165:1390–400
   PubMed Web of Science ®Google Scholar
• Benter IF, Benboubetra M, Hollins AJ, et al. Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vasc Pharmacol 2009;51:236–45
   PubMed Web of Science ®Google Scholar
• Belmadani S, Palen DI, Gonzalez-Villalobos RA, et al. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 2008;57:1629–37
   PubMed Web of Science ®Google Scholar
• Palen DI, Matrougui K. Role of elevated EGFR phosphorylation in the induction of structural remodeling and altered mechanical properties of resistance artery from type 2 diabetic mice. Diabetes Metab Res Rev 2008;24:651–6
   PubMed Web of Science ®Google Scholar
• Akhtar S, Yousif MH, Dhaunsi GS, et al. Activation of ErbB2 and downstream signaling via rho kinases and ERK1/2 contributes to diabetes-induced vascular dysfunction. PLoS One 2013;8:e67813
   PubMed Web of Science ®Google Scholar
• Ono N, Yamazaki T, Nakanishi Y, et al. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci 2012;103:342–9
   PubMed Web of Science ®Google Scholar
• Leow CC, Chesebrough J, Coffman KT, et al. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol Cancer Ther 2009;8:2131–41
   PubMed Web of Science ®Google Scholar
• Hollins AJ, Omidi Y, Benter IF, Akhtar S. Toxicogenomics of drug delivery systems: exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J Drug Target 2007;15:83–8
   PubMed Web of Science ®Google Scholar
• Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011;32:167–73
   PubMed Web of Science ®Google Scholar
• Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol 2011;7:657–71
   PubMedGoogle Scholar
• Oellerich MF, Potente M. FOXOs and sirtuins in vascular growth, maintenance, and aging. Circ Res 2012;110:1238–51
   PubMed Web of Science ®Google Scholar
• Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011;1813:1938–45
   PubMed Web of Science ®Google Scholar
• Portbury AL, Ronnebaum SM, Zungu M, et al. Back to your heart: ubiquitin proteasome system-regulated signal transduction. J Mol Cell Cardiol 2012;52:526–37
   PubMed Web of Science ®Google Scholar
• Maiese K, Shang YC, Chong ZZ, Hou J. Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res 2010;7:59–64
   PubMed Web of Science ®Google Scholar
• Akhtar S, Yousif MH, Chandrasekhar B, Benter, IF. Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia–reperfusion injury. PLoS One 2012;7:e39066
   PubMed Web of Science ®Google Scholar
• Arunachalam G, Samuel SM, Marei I, et al. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol 2014;171:523–35
   PubMed Web of Science ®Google Scholar
• Mortuza R, Chen S, Feng B, et al. High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway. PLoS One 2013;8:e54514
   PubMed Web of Science ®Google Scholar
• Xu F, Wang Y, Cui W, et al. Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-κB pathway. Int J Endocrinol 2014;2014:289327
   PubMedGoogle Scholar
• Mohamed SA, Radtke A, Saraei R, et al. Locally different endothelial nitric oxide synthase protein levels in ascending aortic aneurysms of bicuspid and tricuspid aortic valve. Cardiol Res Pract 2012;2012:165957
   PubMedGoogle Scholar
• Buchwalow IB, Podzuweit T, Samoilova VE, et al. An in situ evidence for autocrine function of NO in the vasculature. Nitric Oxide 2004;10:203–12
   PubMed Web of Science ®Google Scholar
• Galán M, Kassan M, Choi SK, et al. A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus. Hypertension 2012;60:71–80
   PubMed Web of Science ®Google Scholar
• El-Hashim AZ, Renno WM, Raghupathy R, et al. Angiotensin-(1–7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways. Br J Pharmacol 2012;166:1964–76
   PubMed Web of Science ®Google Scholar
• Rivas MA, Tkach M, Beguelin W, et al. Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation. Breast Cancer Res Treat 2010;122:111–24
   PubMed Web of Science ®Google Scholar
• Kassan M, Choi SK, Galán M, et al. Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice. Diabetes Metab Res Rev 2015;31:39–49
   PubMed Web of Science ®Google Scholar
• Gerondakis S, Fulford TS, Messina NL, Grumont RJ. NF-κB control of T cell development. Nat Immunol 2014;15:15–25
   PubMed Web of Science ®Google Scholar
• Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013;12:86. doi: 10.1186/1476-4598-12-86
   PubMed Web of Science ®Google Scholar
• Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 2007;112:375–84
   PubMed Web of Science ®Google Scholar
• Li H, Telemaque S, Miller RE, Marsh JD. High glucose inhibits apoptosis induced by serum deprivation in vascular smooth muscle cells via upregulation of Bcl-2 and Bcl-xl. Diabetes 2005;54:540–5
   PubMed Web of Science ®Google Scholar
• Hall JL, Matter CM, Wang X, Gibbons GH. Hyperglycemia inhibits vascular smooth muscle cell apoptosis through a protein kinase C-dependent pathway. Circ Res 2000;87:574–80
   PubMed Web of Science ®Google Scholar
• Martínez-Hervás S, Vinué A, Núñez L, et al. Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis. Cardiovasc Res 2014;103:324–36
   PubMed Web of Science ®Google Scholar
• Wang P, Xu TY, Guan YF, et al. Vascular smooth muscle cell apoptosis is an early trigger for hypothyroid atherosclerosis. Cardiovasc Res 2014;102:448–59
   PubMed Web of Science ®Google Scholar
• Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep 2014;16:431. doi: 10.1007/s11906-014-0431-2
   PubMed Web of Science ®Google Scholar
• Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des 2013;19:5695–703
   PubMed Web of Science ®Google Scholar